Work

Treatment with Human Mesenchymal Stem Cells (Remestemcel-L) Is Effective in Pediatric Patients with Refractory Acute Graft Versus Host Disease

Year: 2015

Type: article

Abstract: Severe steroid-refractory acute graft-versus-host disease (aGVHD) causes significant morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Early clinical trials of therapy with human mesenchymal stem cells (hMSCs) in pediatric patients with severe aGVHD, resistant to multiple immunosuppressive agents, showed promising results. In this study, we evaluated the risk/benefit profile of remestemcel-L, an off-the-shelf source of culture expanded human mesenchymal stem cells, provided by Mesoblast, Inc.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2014.11.539